Not medical advice: Educational content only. Author is not a doctor. Consult a licensed healthcare professional.
Updated February 2026
A side-by-side comparison of mechanisms, evidence, safety, and key differences.
Critical Warning: Neither fenbendazole nor ivermectin is FDA-approved for cancer treatment. DO NOT combine them without medical supervision due to serious liver toxicity risk. This is educational content only.
| Category | Fenbendazole | Ivermectin |
|---|---|---|
| Drug Type | Veterinary antiparasitic (benzimidazole) | FDA-approved human antiparasitic |
| FDA Approval | Not approved for human use | Approved for parasitic infections |
| Cancer Mechanism | Microtubule disruption, glucose uptake inhibition, p53 activation | WNT/β-catenin inhibition, mitochondrial effects, P-gp modulation |
| Cancer Types Studied | Lymphoma, lung, colon, breast | Breast, colon, ovarian, lung |
| Evidence Level | Preclinical + case reports only | Preclinical + early Phase I/II trials |
| Liver Risk | Documented hepatotoxicity (elevated ALT/AST) | Lower risk at approved doses; elevated at high doses |
| Human Safety Data | Limited (veterinary drug) | Extensive (decades of human use) |
| Combination Risk | HIGH when combined with ivermectin | HIGH when combined with fenbendazole |
| Availability | OTC veterinary, some compounding pharmacies | Prescription or OTC in some states (2025+) |
| Price Range | $30-80/month | $10-50/month |
Both compounds show preclinical promise but neither is proven to treat cancer in humans. Ivermectin has the advantage of decades of human safety data and more advanced clinical trials. Fenbendazole has stronger preclinical anti-cancer mechanisms but higher liver toxicity risk and no FDA approval for human use.
DO NOT use either compound without oncologist supervision. DO NOT combine them due to documented liver toxicity risk.